drugset / Trial / NCT00651651

Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5

NCT00651651 ↗

Phase 3 Completed 450 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare Symbicort with its monocomponents budesonide and formoterol in the treatment of asthma in children and adults

Timeline

Start
2002-08
Primary completion
—
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Formoterol Other / unclassified 9 ug Inhaled

Indications